Quick Answer
SANGAMO THERAPEUTICS, INC reported Net Income of -$122.93 million for fiscal year 2025.
SANGAMO THERAPEUTICS, INC Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$122.93M | -25.5% |
| 2024 | -$97.94M | +62.0% |
| 2023 | -$257.83M | -34.1% |
| 2022 | -$192.28M | -7.8% |
| 2021 | -$178.29M | -47.3% |
| 2020 | -$121.00M | -27.1% |
| 2019 | -$95.19M | -39.3% |
| 2018 | -$68.33M | -25.2% |
| 2017 | -$54.57M | +23.8% |
| 2016 | -$71.66M | -76.1% |
| 2015 | -$40.70M | -54.1% |
| 2014 | -$26.42M | +0.8% |
| 2013 | -$26.62M | -19.6% |
| 2012 | -$22.26M | +37.7% |
| 2011 | -$35.75M | -43.8% |
| 2010 | -$24.85M | -33.7% |
| 2009 | -$18.59M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$34.93M | -427.3% | -74.8% |
| June 30, 2025 | -$19.99M | +44.7% | +34.7% |
| March 31, 2025 | -$30.60M | +37.7% | -386.7% |
| September 30, 2024 | $10.67M | +110.2% | +129.5% |
| June 30, 2024 | -$36.13M | +68.4% | +26.4% |
| March 31, 2024 | -$49.09M | -332.3% | +52.9% |
| September 30, 2023 | -$104.16M | -96.0% | +9.0% |
| June 30, 2023 | -$114.51M | -165.2% | -641.8% |
- SANGAMO THERAPEUTICS, INC showed a decrease of -25.5% in Net Income compared to the prior fiscal year.
- Over the 2009–2025 period, SANGAMO THERAPEUTICS, INC’s net income has declined by 561.4% (from -$18.59 million to -$122.93 million).
- The most recent figure is from SANGAMO THERAPEUTICS, INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: